Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. Its pipeline includes TA-ERT, a fusion protein containing recombinant human alpha-N-acetylglucosaminidase, an enzyme replacement therapy for Sanfilippo Syndrome Type B; Tildacerfont for a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns; and SPR202 for Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds, and a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Incorporated in 2014, Spruce Biosciences is headquartered in South San Francisco, California.
USA